Benjamin Morgan Scirica MD
Senior Physician and Director, Innovation, Cardiovascular Division, Brigham and Women's Hospital; Professor of Medicine, Harvard Medical School; Senior Investigator, TIMI Study Group, Boston, MassachusettsDr. Benjamin Scirica is a senior physician and Director of Innovation in the Cardiovascular Division at Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School. He is a Senior Investigator at the TIMI Study Group (an academic research organization based at Brigham and Women's Hospital that has performed over 75 clinical trials in cardiometabolic diseases).
His research interests center on the risk stratification, management, and the identifation of novel therapies to improve outcomes in patients with acute coronary syndromes and cardiometabolic disorders.
Dr. Scirica has authored or co-authored over 200 peer-reviewed articles and is a reviewer for multiple journals, including The New England Journal of Medicine, JAMA, The Lancet, Circulation, and Journal of the American College of Cardiology (JACC).
Disclosures
- Institutional research support to Brigham and Women’s Hospital from: Amgen; Better Therapeutics; Boehringer Ingelheim; Merck; Novo Nordisk; Pfizer; Verve Therapeutics
- Consulting fees from: AbbVie (DSMB); Amgen; AstraZeneca (DSMB); Bayer; Boehringer Ingelheim (DSMB); Elsevier Practice Update Cardiology; Hanmi (DSMB); Lexeo (DSMB); Novo Nordisk; Verve Therapeutics; and equity in Health [at] Scale; Arboretum Lifescience
Recent Contributions to PracticeUpdate:
- Clinical Picture and Risk for Short-Term Mortality in Cardiogenic Shock
- Cardiac Screening With Electrocardiography, Stress Echocardiography, or Myocardial Perfusion Imaging
- Heart Failure in Patients With Type 2 Diabetes Taking Alogliptin
- ACC.15: SCOT-HEART–Coronary CTA and Nailing the Diagnosis of Coronary Heart Disease
- ACC.15–Dr. Ben Scirica on EMBRACE STEMI
- ACC.15: Lipid-Lowering Effects of Evolocumab–OSLER Trial
- ACC.15: Alirocumab Reduces LDL Levels in the ODESSEY Trial
- ACC.15—Late-Breaking Trial Recommendations From Ben Scirica
- Vorapaxar in Patients With Diabetes and Prior Myocardial Infarction
- Cognitive Function in Cardiac Arrest Survivors With Temperature Management at 33ºC